Indus Gene Expressions Limited - Company Profile

It is a life sciences public limited company based in Chilamathur Mandal, Andhra Pradesh, India, established in 2007.
2007 Chilamathur Mandal, Andhra Pradesh, India Active
Last Updated:
Access Report
About Indus Gene Expressions Limited

Indus Gene Expressions Limited, a active public limited company, was established on 09 February 2007 in Chilamathur Mandal, Andhra Pradesh, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U24231AP2007PLC113311. Registered under ROC Roc Vijayawada. it is unlisted. It has an authorized capital of ₹100.00 Cr and a paid-up capital of ₹92.83 Cr.

Formerly known as Indus Gene Expressions Private Limited, Sri Balaji Biopharmaceuticals India Private Limited. It upholds a compliant status. Employing 29 professional, Its leadership includes Usharani Reddy C (Cfo), Channa Reddy C (Director), Meka Sudhakara Reddy (Additional Director). Past directors included Usharani Reddy C, Vemula Nilima, Mallikarjuna Reddy Beedupalli. It holds ₹32.63 Cr open charges and ₹30.40 Cr settled loans. Its latest AGM occurred on 30 September 2023, with the balance sheet filed on 31 March 2023. It is based at 6-312 Kodur Village, Kanisettipalli Post, Chilamathur Mandal, Andhra Pradesh, 515341.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24231AP2007PLC113311

  • Registration Number

    113311

  • Incorporation Date

    09 February 2007

  • Authorized Capital

    ₹100.00 Cr

  • Paid-Up Capital

    ₹92.83 Cr

  • ROC Code

    Roc Vijayawada

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 100.00 Cr
  • Paid Up Capital ₹ 92.83 Cr
  • Company Age 19 Year, 3 Months
  • Last Filing with ROC 31 Mar 2023
  • Open Charges ₹ 32.63 Cr
  • Satisfied Charges ₹ 30.40 Cr
  • Revenue Growth **** 570.15%
  • Profit Growth **** 142.29%
  • Ebitda **** -156.62%
  • Net Worth 26.98%
  • Total Assets **** 18.00%
Company report

Indus Gene Expressions Limited

Company Report FY 2026-2027

Comprehensive Company Insights

Explore comprehensive insights into Indus Gene Expressions Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Indus Gene Expressions Limited?
Current Directors
Name Designation Appointment Date Status
Usharani Reddy C Cfo 03 Apr 2019 Current
Channa Reddy C Director 06 Nov 2008 Current
Meka Sudhakara Reddy Additional Director 06 May 2022 Current
Avula Sreenivasa Reddy Additional Director 28 Oct 2019 Current
Muktha Puram Krishna Additional Director 28 Sep 2024 Current
Abhinaya Chinthamani Reddy Additional Director 15 Jan 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 30 Mar 2009 Past
Pramod Abcsdd Additional Director 17 Dec 2024 Past
Pramod Abcsdd Director 03 Apr 2019 Past
Pramod Abcsdd Company Secretary 31 Jan 2025 Past
Pramod Abcsdd Director 28 Oct 2019 Past
Pramod Abcsdd Director 24 Feb 2011 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Indus Gene Expressions.

Indus Gene Expressions Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 570.15% increase. The company also saw a substantial improvement in profitability, with a 142.29% increase in profit. The company's net worth Soared by an impressive increase of 26.98%.

Indus Gene Expressions revenue growth over time
Indus Gene Expressions profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 570.15%
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
 18.00%
*******
*******
*******
*******
Profit or Loss
*******
 142.29%
*******
*******
*******
*******
Net Worth
*******
 26.98%
*******
*******
*******
*******
EBITDA
*******
 -156.62%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Indus Gene Expressions?

In 2023, Indus Gene Expressions had a promoter holding of 21.77% and a public holding of 78.23%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹326,300,000.00

Satisfied Charges

₹304,000,000.00

Charges Breakdown by Lending Institutions
  • Syndicate Bank : 29.00 Cr
  • Canara Bank : 3.63 Cr
Latest Charge Details
Date Lender Amount Status
04 Sep 2020 Canara Bank ₹3.63 Cr Open
21 Dec 2019 Syndicate Bank ₹29.00 Cr Open
13 Oct 2014 Andhra Bank ₹30.40 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Indus Gene Expressions?

Unlock and access historical data on people associated with Indus Gene Expressions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Indus Gene Expressions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indus Gene Expressions's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Indus Gene Expressions
Recent Activity within the Organization
  • Director Appointment

    Progress on Abhinaya Chinthamani Reddy was appointed as a Additional Director was appointed as a Additional Director on 15 Jan 2025 & has been associated with this company since 1 year 3 months . was documented.

  • Director Appointment

    Muktha Puram Krishna was appointed as a Additional Director was appointed as a Additional Director on 28 Sep 2024 & has been associated with this company since 1 year 7 months . was recorded as a recent event.

  • Annual General Meeting

    Progress on Indus Gene Expressions Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records. was documented.

  • Balance Sheet

    Progress on Indus Gene Expressions Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Vijayawada. was documented.

  • Director Appointment

    Progress on Meka Sudhakara Reddy was appointed as a Additional Director was appointed as a Additional Director on 06 May 2022 & has been associated with this company since 4 years 6 days . was documented.

  • Charges

    A charge with Canara Bank amounted to Rs. 3.63 Cr with Charge ID 100369900 was registered on 04 Sep 2020. was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Indus Gene Expressions Limited?

The CIN of Indus Gene Expressions Limited is U24231AP2007PLC113311.

Where is Indus Gene Expressions Limited headquartered?

Indus Gene Expressions Limited is headquartered at 6-312 Kodur Village, Kanisettipalli Post, Chilamathur Mandal, Andhra Pradesh, 515341.

When was Indus Gene Expressions Limited incorporated?

Indus Gene Expressions Limited was incorporated on 09 February 2007.

Who are the current directors of Indus Gene Expressions Limited?

The current directors of Indus Gene Expressions Limited are

What is the primary industry of Indus Gene Expressions Limited?

The primary industry of Indus Gene Expressions Limited is Professional, Scientific And Technical.

Is Indus Gene Expressions Limited a listed company?

Indus Gene Expressions Limited is unlisted.

What is the capital structure of Indus Gene Expressions Limited?

The authorized capital of Indus Gene Expressions Limited is ₹100.00 Cr, and the paid-up capital is ₹92.83 Cr.

What is the compliance status of Indus Gene Expressions Limited?

The compliance status of Indus Gene Expressions Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available